UBS Group
ANTX icon

UBS Group’s AN2 Therapeutics ANTX Stock Holding History

UBS Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Buy
74,086
+12,694
+21% +$54.6K ﹤0.01% 6442
2026
Q1 		$210K Buy
61,392
+4,724
+8% +$9.75K ﹤0.01% 6613
2025
Q4 		$64.6K Sell
56,668
-26
-0% -$30 ﹤0.01% 7101
2025
Q3 		$72K Sell
56,694
-5,306
-9% -$6.07K ﹤0.01% 7320
2025
Q2 		$65.7K Sell
62,000
-44,021
-42% -$52.5K ﹤0.01% 7557
2025
Q1 		$144K Sell
106,021
-64,271
-38% -$80.9K ﹤0.01% 6769
2024
Q4 		$235K Buy
+170,292
New +$207K ﹤0.01% 6355
2024
Q3 		– Sell
-17,483
Closed -$37.6K – 9475
2024
Q2 		$37.6K Sell
17,483
-2,091
-11% -$4.98K ﹤0.01% 6904
2024
Q1 		$63.6K Buy
+19,574
New +$213K ﹤0.01% 6408
2023
Q4 		– Sell
-41,046
Closed -$660K – 9268
2023
Q3 		$660K Sell
41,046
-8,627
-17% -$97.7K ﹤0.01% 4434
2023
Q2 		$422K Sell
49,673
-2,552
-5% -$18.3K ﹤0.01% 4967
2023
Q1 		$515K Buy
52,225
+770
+1% +$8.56K ﹤0.01% 4662
2022
Q4 		$490K Buy
51,455
+22,348
+77% +$299K ﹤0.01% 4725
2022
Q3 		$506K Sell
29,107
-19,260
-40% -$225K ﹤0.01% 4327
2022
Q2 		$375K Buy
48,367
+47,209
+4,077% +$625K ﹤0.01% 4478
2022
Q1 		$17K Buy
+1,158
New +$17.6K ﹤0.01% 7631

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

UBS Group's ANTX Position: Q2 2026 in Review

UBS Group increased its AN2 Therapeutics (ANTX) stake by 21% in Q2 2026, buying an estimated $54.6K and bringing the position to 74,086 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #6442.

UBS Group first reported a position in ANTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $660K in Q3 2023. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • UBS Group held 74,086 shares of AN2 Therapeutics worth $359K as of Q2 2026.
  • UBS Group bought 12,694 AN2 Therapeutics shares in Q2 2026, an estimated $54.6K.
  • AN2 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6442 holding.
  • UBS Group first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • UBS Group's AN2 Therapeutics position peaked at $660K in Q3 2023.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.